Beta Bionics (NASDAQ:BBNX) Insider Sells 775 Shares of Company Stock

Key Points

• Insider selling: Mark Hopman sold 775 Beta Bionics shares for $13,446 at an average price of $17.35, reducing his direct ownership by 1.38% to 55,334 shares. He has also made several larger sales since early September.
• Stock and financial performance: BBNX recently traded at $16.35, below its 50-day average of $19.04, while the company reported a quarterly loss of $0.53 per share but beat analyst expectations. Analysts project a full-year loss of $2.02 per share.
• Heightened legal and regulatory risks: Multiple law firms are promoting a securities class action alleging investors were misled about the iLet insulin-delivery system and related compliance issues. Investors have until November 3, 2026, to seek lead-plaintiff status, potentially adding volatility and reputational risk.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 775 shares of the company's stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $17.35, for a total value of $13,446.25. Following the transaction, the insider directly owned 55,334 shares of the company's stock, valued at approximately $960,044.90. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mark Hopman also recently made the following trade(s):

• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The shares were sold at an average price of $18.96, for a total value of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Price Performance

NASDAQ BBNX traded down $0.96 on Friday, hitting $16.35. The company had a trading volume of 660,831 shares, compared to its average volume of 1,176,239. The company's fifty day moving average price is $19.04 and its 200-day moving average price is $15.19. The company has a market capitalization of $735.59 million, a PE ratio of -9.91 and a beta of 3.39. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million for the quarter. On average, sell-side analysts anticipate that Beta Bionics, Inc. will post -2.02 EPS for the current year.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Beta Bionics and certain executives on behalf of investors who purchased shares from July 30, 2025, through February 24, 2026. The lawsuit alleges that the company misled investors about its automated insulin-delivery system, iLet, and related operational and compliance issues. Hagens Berman class-action announcement
• Negative Sentiment: The allegations follow reported FDA concerns involving the iLet system, including claims that Beta Bionics abandoned a built-in safety feature for the dosing algorithm and failed to investigate more than 18,000 customer complaints. The articles state that successive revelations contributed to a roughly 72% decline in the stock during the relevant period. These claims have not been proven in court. SueWallSt shareholder notice
• Negative Sentiment: Investors have until November 3, 2026, to seek appointment as lead plaintiff. The growing number of law-firm solicitations increases visibility around potential litigation costs, reputational damage, regulatory uncertainty and possible disruption to the company’s iLet business, all of which may keep volatility elevated. Kaplan Fox deadline announcement

Institutional Investors Weigh In On Beta Bionics

A number of large investors have recently modified their holdings of BBNX. Caitong International Asset Management Co. Ltd lifted its stake in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock worth $61,000 after buying an additional 1,818 shares in the last quarter. Legal & General Group Plc acquired a new position in Beta Bionics during the second quarter worth about $62,000. The Manufacturers Life Insurance Company purchased a new stake in Beta Bionics during the 2nd quarter valued at about $172,000. Ieq Capital LLC purchased a new stake in Beta Bionics during the 2nd quarter valued at about $229,000. Finally, Quantbot Technologies LP acquired a new stake in Beta Bionics in the 2nd quarter valued at about $264,000.

Wall Street Analysts Forecast Growth

BBNX has been the topic of several research analyst reports. Robert W. Baird lifted their price objective on Beta Bionics from $14.00 to $16.00 and gave the stock a "neutral" rating in a report on Tuesday, September 15th. Weiss Ratings raised Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. William Blair assumed coverage on Beta Bionics in a research report on Friday, August 21st. They issued a "market perform" rating on the stock. Wells Fargo & Company started coverage on Beta Bionics in a research report on Wednesday, September 23rd. They issued an "overweight" rating and a $28.00 target price on the stock. Finally, The Goldman Sachs Group lifted their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.00.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company's dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person's body weight and meal announcements as key inputs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.